Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data and to derive novel conclusions on the underlying mechanisms of disease. The platform is currently being used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.